Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 5/20 | 0.46 |
| ▸ | GSK3A | P49840 | 2/20 | 0.44 |
| ▸ | GSK3B | P49841 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | WRN | Q14191 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 3/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16038491 | 1.00 | MGLL (0.46) | MGLLGSK3AGSK3BMEN1KMT2A | |
| SCHEMBL24938802 | 0.85 | HCAR2 (0.49) | MGLLGSK3AGSK3BMEN1KMT2A | |
| SCHEMBL26032830 | 0.85 | MGLL (0.47) | MGLLGSK3AGSK3BMEN1KMT2A | |
| SCHEMBL16090944 | 0.81 | HCAR2 (0.42) | MEN1KMT2ANFE2L2HCAR2KEAP1 | |
| Diroximel Fumarate SCHEMBL15511916 | 0.81 | HPGD (0.43) | MEN1KMT2ANFE2L2HCAR2KEAP1 | |
| SCHEMBL16090941 | 0.81 | MEN1 (0.46) | MEN1KMT2ANFE2L2HCAR2KEAP1 | |
| Diroximel Fumarate SCHEMBL23133759 | 0.81 | HPGD (0.43) | MEN1KMT2ANFE2L2HCAR2KEAP1 | |
| Diroximel Fumarate SCHEMBL15499960 | 0.81 | HPGD (0.43) | MEN1KMT2ANFE2L2HCAR2KEAP1 | |
| SCHEMBL23352295 | 0.79 | HCAR2 (0.41) | MEN1KMT2ANFE2L2HCAR2KEAP1 | |
| SCHEMBL16037826 | 0.79 | HCAR2 (0.41) | MEN1KMT2ANFE2L2HCAR2KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4230264-B1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DESEASES | ALKERMES PHARMA IRELAND LTD (IE) | 2026-01-28 | — | — | EP | disclosed |
| US-20250127747-A1 | Prodrugs of Fumarates and Their Use in Treating Various Diseases | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2025-04-24 | — | — | US | disclosed |
| US-12076306-B2 | Prodrugs of fumarates and their use in treating various diseases | ALKERMES PHARMA IRELAND LIMITED (IE) | 2024-09-03 | — | — | US | disclosed |
| US-20240024275-A1 | Prodrugs of Fumarates and Their Use in Treating Various Diseases | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2024-01-25 | — | — | US | disclosed |
| EP-3366668-B1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DESEASES | ALKERMES PHARMA IRELAND LTD (IE) | 2023-06-21 | — | — | EP | disclosed |
| US-11679092-B2 | Prodrugs of fumarates and their use in treating various diseases | ALKERMES PHARMA IRELAND LIMITED (IE) | 2023-06-20 | — | — | US | disclosed |
| US-20220096419-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2022-03-31 | — | — | US | disclosed |
| US-11083703-B2 | Prodrugs of fumarates and their use in treating various diseases | ALKERMES PHARMA IRELAND LIMITED (IE) | 2021-08-10 | — | — | US | disclosed |
| US-20200352893-A1 | Prodrugs of Fumarates and Their Use in Treating Various Diseases | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2020-11-12 | — | — | US | disclosed |
| US-10596140-B2 | Prodrugs of fumarates and their use in treating various diseases | ALKERMES PHARMA IRELAND LIMITED (IE) | 2020-03-24 | — | — | US | disclosed |
| US-10406133-B2 | Prodrugs of fumarates and their use in treating various diseases | ALKERMES PHARMA IRELAND LIMITED (IE) | 2019-09-10 | — | — | US | disclosed |
| US-20190201367-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2019-07-04 | — | — | US | disclosed |
| US-10080733-B2 | Prodrugs of fumarates and their use in treating various diseases | ALKERMES PHARMA IRELAND LIMITED (IE) | 2018-09-25 | — | — | US | disclosed |
| EP-3366668-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DESEASES | Alkermes Pharma Ireland Limited (IE) | 2018-08-29 | — | — | EP | disclosed |
| US-20180042881-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-02-15 | — | — | US | disclosed |
| US-9775823-B2 | Prodrugs of fumarates and their use in treating various diseases | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-10-03 | — | — | US | disclosed |
| US-20170095439-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2017-04-06 | — | — | US | disclosed |
| US-9505776-B2 | Prodrugs of fumarates and their use in treating various diseases | ALKERMES PHARMA IRELAND LIMITED (IE) | 2016-11-29 | — | — | US | disclosed |
| US-20140275048-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | ALKERMES PHARMA IRELAND LIMITED (IE) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275048-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | FH, FAH, GLS2 | MGLL 2096/4885GSK3A 1684/4885GSK3B 1335/4885 |
| US-20220096419-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | FH, FAH, GLS2 | MGLL 2096/4885GSK3A 1684/4885GSK3B 1335/4885 |
| US-11083703-B2 | Prodrugs of fumarates and their use in treating various diseases | FH, FAH, GLS2 | MGLL 2096/4885GSK3A 1684/4885GSK3B 1335/4885 |
| US-10406133-B2 | Prodrugs of fumarates and their use in treating various diseases | FH, FAH, GLS2 | MGLL 2096/4885GSK3A 1684/4885GSK3B 1335/4885 |
| US-11679092-B2 | Prodrugs of fumarates and their use in treating various diseases | FH, FAH, GLS2 | MGLL 2096/4885GSK3A 1684/4885GSK3B 1335/4885 |
| US-10596140-B2 | Prodrugs of fumarates and their use in treating various diseases | FH, FAH, GLS2 | MGLL 2096/4885GSK3A 1684/4885GSK3B 1335/4885 |
| US-10080733-B2 | Prodrugs of fumarates and their use in treating various diseases | FH, FAH, GLS2 | MGLL 2096/4885GSK3A 1684/4885GSK3B 1335/4885 |
| US-20200352893-A1 | Prodrugs of Fumarates and Their Use in Treating Various Diseases | FH, FAH, GLS2 | MGLL 2096/4885GSK3A 1684/4885GSK3B 1335/4885 |
| US-20240024275-A1 | Prodrugs of Fumarates and Their Use in Treating Various Diseases | FH, FAH, GLS2 | MGLL 2096/4885GSK3A 1684/4885GSK3B 1335/4885 |
| US-20190201367-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | FH, FAH, GLS2 | MGLL 2096/4885GSK3A 1684/4885GSK3B 1335/4885 |
| US-12076306-B2 | Prodrugs of fumarates and their use in treating various diseases | FH, FAH, GLS2 | MGLL 2096/4885GSK3A 1684/4885GSK3B 1335/4885 |
| US-20250127747-A1 | Prodrugs of Fumarates and Their Use in Treating Various Diseases | FH, FAH, GLS2 | MGLL 2096/4885GSK3A 1684/4885GSK3B 1335/4885 |
| US-20180042881-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | FH, FAH, GLS2 | MGLL 2096/4885GSK3A 1684/4885GSK3B 1335/4885 |
| US-20170095439-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | FH, FAH, GLS2 | MGLL 2096/4885GSK3A 1684/4885GSK3B 1335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.